Impact of HPMC on inhibiting crystallization and improving permeability of curcumin amorphous solid dispersions

被引:61
作者
Fan, Na [1 ]
He, Zhonggui [1 ]
Ma, Pingping [1 ]
Wang, Xin [1 ]
Li, Chang [1 ]
Sun, Jin [1 ]
Sun, Yinghua [1 ]
Li, Jing [1 ]
机构
[1] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang, Liaoning, Peoples R China
关键词
Curcumin amorphous solid dispersions; Inhibit crystallization; Improve permeability; Hydrogen bonding; Ionic interactions; CELLULOSE DERIVATIVE MATRICES; PHASE-BEHAVIOR; DANAZOL SOLUTIONS; AQUEOUS-MEDIA; STABILITY; SOLUBILITY; POLYMERS; DRUG; SUPERSATURATION; RESVERATROL;
D O I
10.1016/j.carbpol.2017.12.004
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The purpose of this paper was to elucidate the impacts of hydroxypropylmethyl cellulose E5 as assistant excipient on inhibiting crystallization and improving membrane permeability in curcumin amorphous solid dispersions that formulated by Eudragit E100. Intermolecular interactions formed between curcumin and polymers were probed using in situ Raman imaging and infrared spectroscopy. The abilities of hydroxypropylmethyl cellulose E5 in inhibiting crystallization and improving membrane permeability were confirmed by fluorescence spectroscopy, dynamic light scattering analysis and in vitro permeability experiment. The results demonstrated hydroxypropylmethyl cellulose E5 was significant in maintaining the amorphous drug concentration owing to the hydrogen bond interactions formed with curcumin, rending its ability to inhibit crystallization by reducing drug droplet size. Furthermore, the addition of hydroxypropylmethyl cellulose E5 in curcumin amorphous solid dispersions promoted drug membrane permeability through lowering the order level of phospholipid bilayer layer.
引用
收藏
页码:543 / 550
页数:8
相关论文
共 31 条
[1]  
Aggarwal BB, 2003, ANTICANCER RES, V23, P363
[2]   Assessment of the Amorphous "Solubility" of a Group of Diverse Drugs Using New Experimental and Theoretical Approaches [J].
Almeida e Sousa, Luis ;
Reutzel-Edens, Susan M. ;
Stephenson, Gregory A. ;
Taylor, Lynne S. .
MOLECULAR PHARMACEUTICS, 2015, 12 (02) :484-495
[3]   Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition [J].
Bernabé-Pineda, M ;
Ramírez-Silva, MT ;
Romero-Romo, M ;
Gonzádlez-Vergara, E ;
Rojas-Hernández, A .
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2004, 60 (05) :1091-1097
[4]  
Chaudhari S.P., 2015, J PHARM SCI PHARM, V2, P259, DOI DOI 10.1166/JPSP.2015.1066
[5]   Impact of Surfactants on the Crystallization of Aqueous Suspensions of Celecoxib Amorphous Solid Dispersion Spray Dried Particles [J].
Chen, Jie ;
Ormes, James D. ;
Higgins, John D. ;
Taylor, Lynne S. .
MOLECULAR PHARMACEUTICS, 2015, 12 (02) :533-541
[6]   Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats [J].
Imbaby, S. ;
Ewais, M. ;
Essawy, S. ;
Farag, N. .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2014, 33 (08) :800-813
[7]   Exploiting the Phenomenon of Liquid-Liquid Phase Separation for Enhanced and Sustained Membrane Transport of a Poorly Water-Soluble Drug [J].
Indulkar, Anura S. ;
Gao, Yi ;
Raina, Shweta A. ;
Zhang, Geoff G. Z. ;
Taylor, Lynne S. .
MOLECULAR PHARMACEUTICS, 2016, 13 (06) :2059-2069
[8]   Characterization of Supersaturated Danazol Solutions - Impact of Polymers on Solution Properties and Phase Transitions [J].
Jackson, Matthew J. ;
Kestur, Umesh S. ;
Hussain, Munir A. ;
Taylor, Lynne S. .
PHARMACEUTICAL RESEARCH, 2016, 33 (05) :1276-1288
[9]   Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type [J].
Jackson, Matthew J. ;
Kestur, Umesh S. ;
Hussain, Munir A. ;
Taylor, Lynne S. .
MOLECULAR PHARMACEUTICS, 2016, 13 (01) :223-231
[10]   Impact of Polymers on the Precipitation Behavior of Highly Supersaturated Aqueous Danazol Solutions [J].
Jackson, Matthew J. ;
Toth, Scott J. ;
Kestur, Umesh S. ;
Huang, Jun ;
Qian, Feng ;
Hussain, Munir A. ;
Simpson, Garth J. ;
Taylor, Lynne S. .
MOLECULAR PHARMACEUTICS, 2014, 11 (09) :3027-3038